Risk-stratified hepatocellular carcinoma screening according to the degree of obesity and progression to cirrhosis for diabetic patients with metabolic dysfunction-associated steatotic liver disease (MASLD) in Japan: a cost-effectiveness study.

ABSTRACT:

Objective

To evaluate the cost-effectiveness of risk-stratified hepatocellular carcinoma (HCC) screening in diabetic patients with metabolic dysfunction-associated steatotic liver disease (MASLD).

Design

A state-transition model from a healthcare payer perspective on a lifetime horizon.

Setting

Japan.

Population

A hypothetical cohort of 50-year-old diabetic patients with MASLD risk-stratified according to degree of obesity and progression to cirrhosis. Metabolic dysfunction-associated steatotic liver (MASL), metabolic dysfunction-associated steatohepatitis (MASH) and MASH cirrhosis are progressive manifestations of this specific type of liver disease.

Intervention

Abdominal ultrasound (US), US with alpha-fetoprotein (AFP), US with AFP and lectin-reactive

SUBMITTER: Kowada A 

PROVIDER: S-EPMC11552604 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature